Your session is about to expire
← Back to Search
Filgrastim vs Pegfilgrastim for Breast Cancer
Study Summary
This trial will compare the amount of bone pain experienced by breast cancer patients who receive a single dose of Pegfilgrastim to those who receive 5 doses of daily filgrastim while undergoing neoadjuvant/adjuvant chemotherapy.
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to filgrastim or pegfilgrastim.
- Group 1: Pegfilgrastim
- Group 2: 5 Days of Filgrastim
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are the maximum capacity for this experiment?
"Affirmative, the information hosted on clinicaltrials.gov shows that this medical study is still recruiting participants. The trial was first posted on June 9th 2021 and most recently edited November 5th 2022; 232 people are required from two different sites."
Are volunteers still being recruited for this investigation?
"Clinicaltrials.gov affirms that recruitment is in progress for this medical experiment, which was posted on June 9th 2021 and adjusted as recently as November 5th 2022."
What potential hazards have been associated with the use of Pegfilgrastim?
"There is already regulatory approval for Pegfilgrastim, which has been granted a safety score of 3."
What conditions do physicians typically prescribe Pegfilgrastim to treat?
"Pegfilgrastim is most commonly administered to alleviate severe congenital neutropenia, though it may also provide relief from acute leukemia and other malignant neoplasms."
To what extent has Pegfilgrastim been utilized in other clinical experiments?
"Currently, 172 trials are underway that involve Pegfilgrastim. 40 of these studies have advanced to the third and final phase while 5807 sites across the world are running tests regarding this drug's efficacy. The majority of clinical research is taking place in Saint Louis, Missouri."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger